
About DNA Nanobots
DNA Nanobots is a Healthcare company based in Powell (United States) founded in 2021 by Melika Shahhosseini and Christopher Lucas. Targeted chemotherapy, vaccines, and gene therapy are delivered via nanotechnology. DNA Nanobots has raised $3.5 million across 2 funding rounds. DNA Nanobots offers products and services including DNA Nanoparticle Platform and Gene Therapy Delivery. Its focus areas include Biopharma Outsourcing, CDMO, Small Molecules & Peptides and Formulation. Its legal entity is DNA Nanobots, LLC. Its competitors include Flashpoint Therapeutics and OSEM; 1 of its 2 listed competitors has raised funding.
Company details
DNA Nanobots was founded in 2021 in Powell, United States, as a biotech firm. Nanotechnology is applied to enable precise delivery of chemotherapy, vaccines, and gene therapy. A technology for efficient and dependable transport has been created. Operations center on building biopharma collaborations, supported by a recent pre-seed funding round. The focus remains on advancing therapeutic applications in the sector.
- Headquarters Powell, United States
- Founders Melika Shahhosseini, Christopher Lucas
- SectorsHealthcare
- Emailβ’β’β’β’β’β’β’β’
- Website dnananobots.com
- Social LinkedIn X
- Legal Name Dna Nanobots, Llc
- Total Equity Funding$3.5M (USD)
in 2 rounds
- Latest Funding Round$3.5M (USD), Series A
Dec 2025
Products & Services of DNA Nanobots
DNA Nanobots offers a comprehensive portfolio of products and services, including DNA Nanoparticle Platform and Gene Therapy Delivery.
Provides targeted delivery for drugs and genes using nanotechnology
Enables non-viral gene delivery to specific tissues for treatment
Funding Insights of DNA Nanobots
DNA Nanobots has successfully raised a total of $3.5M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $3.5 million completed in December 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $3.5M
- Total Rounds 2
- Last Round Series A β $3.5M
All 2 funding rounds of DNA Nanobots with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2025 | $3.5M | Series A | β | β | β |
| Jan 2024 | Seed | β | β | β |
People of DNA Nanobots
2 people are tracked at DNA Nanobots (2 in leadership).
| Name | Role | Group |
|---|---|---|
Melika Shahhosseini | Co-Founder | Leadership |
Christopher Lucas | Co-Founder | Leadership |
Complete people profiles for DNA Nanobots
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of DNA Nanobots
3 dated milestones of DNA Nanobots across 4 years, from founding to its latest funding, stage changes and deals.
- Founded DNA Nanobots is founded.
- Funding First funding round.
- Funding Latest funding round, Series A, of $3.5M.
Competitors of DNA Nanobots
DNA Nanobots has 2 listed competitors in our database, 1 of them funded. They include Flashpoint Therapeutics and OSEM.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| flashpoint.bio | 2022 | Palo Alto, United States | $10M | Flashpoint Therapeutics is developing nanotherapeutic candidates that can deliver precise RNA, DNA, and peptide payloads to specific cells at the right time. | ||
| osem.bio | 2023 | Marina Del Rey, United States | An automated platform utilizing microfluidics for biopharmaceutical processes. |
Detailed competitors of DNA Nanobots
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of DNA Nanobots
The website of DNA Nanobots (dnananobots.com) receives about 1.1K visits a month.
- Monthly visits1.1K
▲ 107.4% vs previous month
Top companies in Biopharma Outsourcing & Drug Delivery
3 companies that operate in the same segment as DNA Nanobots (Biopharma Outsourcing & Drug Delivery) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Suite solutions are provided for payers and healthcare providers. | 1998 | Princeton, New Jersey, United States | USD 220 M | USD 374.1 M | 5,666 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Dna Nanobots
Complete news archive for DNA Nanobots
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about DNA Nanobots
DNA Nanobots was founded in 2021 and raised its 1st funding round 3 years after it was founded.
DNA Nanobots is headquartered in Powell, United States. It is registered at Powell, Wyoming, United States.
DNA Nanobots is a funded company, having raised a total of $3.5M across 2 funding rounds to date.
DNA Nanobots was founded in 2021 in Powell, United States, as a biotech firm. Nanotechnology is applied to enable precise delivery of chemotherapy, vaccines, and gene therapy. A technology for efficient and dependable transport has been created. Operations center on building biopharma collaborations, supported by a recent pre-seed funding round. The focus remains on advancing therapeutic applications in the sector.
DNA Nanobots's top competitors include Flashpoint Therapeutics and OSEM.
DNA Nanobots offers DNA Nanoparticle Platform and Gene Therapy Delivery.
DNA Nanobots operates through Dna Nanobots, Llc.
